# Contact Reviews Wolverine: Editorial Queries on the BPC-157 TB-500 Review

> Contact Reviews Wolverine with editorial queries or corrections about our BPC-157 TB-500 research review. Editorial project only — not a clinic, not a vendor, no medical advice.

Corrections, citation questions, and editorial queries are welcome. Clinical and purchasing requests are not something we can help with.

## Editorial queries and corrections

Reviews Wolverine welcomes editorial correspondence about its BPC-157 TB-500 research review: corrections, citation questions, and pointers to peer-reviewed studies we should consider. If you believe a finding is mischaracterized or a citation is wrong, tell us which page and which reference and we will check it against the source.

The most useful messages are specific. A study we missed, a PubMed identifier that does not resolve, a dose we reported in the wrong units, a place where the blend and a single constituent have been conflated — those are the corrections that improve the review. Where a published study changes the picture, we add it and note the change rather than quietly editing the record.

Use the form below for editorial matters. We read every message, and we update the review when the published record warrants it. We do not, however, respond to requests for medical guidance or sourcing — see below for why.

## What we cannot help with

We are an editorial project, not a clinic and not a vendor. We cannot provide medical advice, recommend doses, evaluate your situation, or tell you whether the blend is appropriate for you — those are questions for a licensed prescriber. We do not sell, supply, source, or price any peptide, and we cannot point you to somewhere that does. Messages asking where to buy the blend, what to inject, or how to dose will not receive a substantive reply, because answering them is neither our role nor within what the published record supports.

For regulatory and access questions, the [Wolverine legal status and FDA 503A category](/legal-status) page sets out the present-tense FDA record, including the scheduled 2026 advisory-committee review. For the evidence itself, start with [BPC-157 and TB-500 mechanisms in review](/research), and for the contested pairing claim see the combination-research page. Anything we publish is general information, not medical or legal advice.

---

The BPC-157 TB-500 record played back like a two-sided release — each peptide read against its own studies on its own side, the combination track left silent because no controlled trial recorded it, and the FDA 503A status printed in the liner notes; no clinic pressed it and nothing here is for sale.